Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells

Biomedicine and Pharmacotherapy

Volumn 88, Issue , 2017, Pages 708-714

  Chen, Yu Chia ^a   Chang, Jan Gowth ^b,c   Liu, Ting Yuan ^a   Jong, Yuh Jyh ^a,d,e   Cheng, Wei Lin ^f   Yuo, Chung Yee ^g  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Securinine; Spinal muscular atrophy; Survival motor neuron gene; Tra2 beta1

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PROTEIN SAM68; SECURININE; SURVIVAL MOTOR NEURON PROTEIN 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TRA2 BETA1; UNCLASSIFIED DRUG; AZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; FUSED HETEROCYCLIC RINGS; LACTONE; PIPERIDINE DERIVATIVE; SERINE ARGININE RICH SPLICING FACTOR; SMN2 PROTEIN, MOUSE; TRA2B PROTEIN, MOUSE;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXON; FIBROBLAST CULTURE; GENE EXPRESSION; GENETIC TRANSCRIPTION; LUCIFERASE ASSAY; LYMPHOID CELL LINE; MOUSE; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SPINAL MUSCULAR ATROPHY; ANIMAL; BIOSYNTHESIS; CELL LINE; GENETICS; LYMPHOID TISSUE; METABOLISM; PATHOPHYSIOLOGY; PROTEIN SPLICING;

ANIMALS; AZEPINES; CELL LINE; CENTRAL NERVOUS SYSTEM STIMULANTS; EXONS; HETEROCYCLIC COMPOUNDS, BRIDGED-RING; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; LACTONES; LYMPHOID TISSUE; MICE; MUSCULAR ATROPHY, SPINAL; PIPERIDINES; PROTEIN SPLICING; RNA, MESSENGER; SERINE-ARGININE SPLICING FACTORS; SURVIVAL OF MOTOR NEURON 2 PROTEIN;

EID: 85010857508     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.01.104     Document Type: Article

References (44)

1. [1] Harding, B.N., Kariya, S., Monani, U.R., Chung, W.K., Benton, M., et al. Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol. Exp. Neurol. 74 (2015), 15–24.
2. [2] Ogino, S., Leonard, D.G., Rennert, H., Ewens, W.J., Wilson, R.B., Genetic risk assessment in carrier testing for spinal muscular atrophy. Am. J. Med. Genet. 110 (2002), 301–307.
3. [3] Edens, B.M., Ajroud-Driss, S., Ma, L., Ma, Y.C., Molecular mechanisms and animal models of spinal muscular atrophy. Biochim. Biophys. Acta 1852 (2014), 685–692.
4. [4] Pearn, J., Classification of spinal muscular atrophies. Lancet 1 (1980), 919–922.
5. [5] Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80 (1995), 155–165.
6. [6] Lorson, C.L., Hahnen, E., Androphy, E.J., Wirth, B., A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 6307–6311.
7. [7] Cartegni, L., Krainer, A.R., Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 30 (2002), 377–384.
8. [8] Cartegni, L., Hastings, M.L., Calarco, J.A., de Stanchina, E., Krainer, A.R., Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am. J. Hum. Genet. 78 (2006), 63–77.
9. [9] Kashima, T., Manley, J.L., A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. 34 (2003), 460–463.
10. [10] Young, P.J., DiDonato, C.J., Hu, D., Kothary, R., Androphy, E.J., et al. SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2 beta 1. Hum. Mol. Genet. 11 (2002), 577–587.
11. [11] Hofmann, Y., Lorson, C.L., Stamm, S., Androphy, E.J., Wirth, B., Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 9618–9623.
12. [12] Bose, J.K., Wang, I.F., Hung, L., Tarn, W.Y., Shen, C.K., TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. J. Biol. Chem. 283 (2008), 28852–28859.
13. [13] Singh, N.N., Seo, J., Ottesen, E.W., Shishimorova, M., Bhattacharya, D., et al. TIA1 prevents skipping of a critical exon associated with spinal muscular atrophy. Mol. Cell. Biol. 31 (2011), 935–954.
14. [14] Pedrotti, S., Bielli, P., Paronetto, M.P., Ciccosanti, F., Fimia, G.M., et al. The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy. EMBO J. 29 (2010), 1235–1247.
15. [15] Kashima, T., Rao, N., David, C.J., Manley, J.L., hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. Hum. Mol. Genet. 16 (2007), 3149–3159.
16. [16] Chen, H.H., Chang, J.G., Lu, R.M., Peng, T.Y., Tarn, W.Y., The RNA binding protein hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2 (SMN2) gene. Mol. Cell. Biol. 28 (2008), 6929–6938.
17. [17] Hofmann, Y., Wirth, B., hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1. Hum. Mol. Genet. 11 (2002), 2037–2049.
18. [18] Wee, C.D., Havens, M.A., Jodelka, F.M., Hastings, M.L., Targeting SR proteins improves SMN expression in spinal muscular atrophy cells. PLoS One, 9, 2014, e115205.
19. [19] Sleeman, J., Small nuclear RNAs and mRNAs: linking RNA processing and transport to spinal muscular atrophy. Biochem. Soc. Trans. 41 (2013), 871–875.
20. [20] Rossoll, W., Jablonka, S., Andreassi, C., Kroning, A.K., Karle, K., et al. Smn the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J. Cell Biol. 163 (2003), 801–812.
21. [21] Piazzon, N., Schlotter, F., Lefebvre, S., Dodre, M., Mereau, A., et al. Implication of the SMN complex in the biogenesis and steady state level of the signal recognition particle. Nucleic Acids Res. 41 (2013), 1255–1272.
22. [22] Kerr, D.A., Nery, J.P., Traystman, R.J., Chau, B.N., Hardwick, J.M., Survival motor neuron protein modulates neuron-specific apoptosis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 13312–13317.
23. [23] Bachand, F., Boisvert, F.M., Cote, J., Richard, S., Autexier, C., The product of the survival of motor neuron (SMN) gene is a human telomerase-associated protein. Mol. Biol. Cell 13 (2002), 3192–3202.
24. [24] Cauchi, R.J., Gem depletion: amyotrophic lateral sclerosis and spinal muscular atrophy crossover. CNS Neurosci. Ther. 20 (2014), 574–581.
25. [25] Seo, J., Howell, M.D., Singh, N.N., Singh, R.N., Spinal muscular atrophy: an update on therapeutic progress. Biochim. Biophys. Acta 1832 (2013), 2180–2190.
26. [26] Zhang, M.L., Lorson, C.L., Androphy, E.J., Zhou, J., An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther. 8 (2001), 1532–1538.
27. [27] Liang, W.C., Yuo, C.Y., Chang, J.G., Chen, Y.C., Chang, Y.F., et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. J. Neurol. Sci. 268 (2008), 87–94.
28. [28] Chang, J.G., Hsieh-Li, H.M., Jong, Y.J., Wang, N.M., Tsai, C.H., et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 9808–9813.
29. [29] Cashman, N.R., Durham, H.D., Blusztajn, J.K., Oda, K., Tabira, T., et al. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev. Dyn. 194 (1992), 209–221.
30. [30] Beutler, J.A., Karbon, E.W., Brubaker, A.N., Malik, R., Curtis, D.R., et al. Securinine alkaloids: a new class of GABA receptor antagonist. Brain Res. 330 (1985), 135–140.
31. [31] Liu, Q., Dreyfuss, G., A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 15 (1996), 3555–3565.
32. [32] Hsieh-Li, H.M., Chang, J.G., Jong, Y.J., Wu, M.H., Wang, N.M., et al. A mouse model for spinal muscular atrophy. Nat. Genet. 24 (2000), 66–70.
33. [33] Raj, D., Luczkiewicz, M., Securinega suffruticosa. Fitoterapia 79 (2008), 419–427.
34. [34] Huang, K.C., The Pharmacology of Chinese Herbs. second ed., 1998, CRC Press.
35. [35] Dimond, E.G., Medical education and care in People's Republic of China. JAMA 218 (1971), 1552–1557.
36. [36] Gupta, K., Chakrabarti, A., Rana, S., Ramdeo, R., Roth, B.L., et al. Securinine, a myeloid differentiation agent with therapeutic potential for AML. PLoS One, 6, 2011, e21203.
37. [37] Copperman, R., Copperman, G., Der Marderosian, A., From Asia securinine–a central nervous stimulant is used in treatment of amytrophic lateral sclerosis. Pa Med. 76 (1973), 36–41.
38. [38] Rana, S., Gupta, K., Gomez, J., Matsuyama, S., Chakrabarti, A., et al. Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells. FASEB J. 24 (2010), 2126–2134.
39. [39] Li, M., Han, S., Zhang, G., Wang, Y., Ji, Z., Antiproliferative activity and apoptosis-inducing mechanism of L-securinine on human breast cancer MCF-7 cells. Pharmazie 69 (2014), 217–223.
40. [40] Natasha, G., Brandom, K.G., Young, E.C., Young, P.J., Valproate and spinal muscular atrophy (Review). Mol. Med. Rep. 1 (2008), 161–165.
41. [41] Darbar, I.A., Plaggert, P.G., Resende, M.B., Zanoteli, E., Reed, U.C., Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurol., 11, 2011, 36.
42. [42] Tiziano, F.D., Lomastro, R., Pinto, A.M., Messina, S., D'Amico, A., et al. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J. Med. Genet. 47 (2010), 856–858.
43. [43] Brahe, C., Vitali, T., Tiziano, F.D., Angelozzi, C., Pinto, A.M., et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. 13 (2005), 256–259.
44. [44] Naryshkin, N.A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345 (2014), 688–693.